Retro Biosciences stock
Private-market facts for current and former Retro Biosciences employees researching their stock.
Overview
Retro Biosciences is a longevity research company working on cell reprogramming, autophagy, and plasma-inspired therapeutics to extend healthy human lifespan.
Selling Retro Biosciences shares
Why shareholders consider selling
Shareholders in Retro Biosciences may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Retro Biosciences does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Retro Biosciences stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Retro Biosciences shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Retro Biosciences shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series A round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Retro Biosciences shareholders
Exploring equity in Retro Biosciences often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Retro Biosciences most recently raised a Series A round in June 2024. Total funding raised to date is approximately $270M.
Lead investors in this round include Redpoint Ventures.
Founders & company background
Retro Biosciences was founded in 2021 by Joe Betts-LaCroix and is headquartered in Redwood City, CA.
Investors
Industry
Similar private companies
Latest Retro Biosciences news
Frequently asked questions
- Is Retro Biosciences still a private company?
- Yes, Retro Biosciences is currently a private company.
- What is Retro Biosciences's latest funding round?
- Retro Biosciences's most recent known round is Series A, raised in June 2024.
- What is Retro Biosciences's valuation?
- Retro Biosciences's valuation has not been publicly disclosed.
- Who are the investors in Retro Biosciences?
- Notable investors include Redpoint Ventures.
- Can I sell my Retro Biosciences stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Retro Biosciences stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Retro Biosciences data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.